Results 251 to 260 of about 134,020 (288)
Some of the next articles are maybe not open access.
Journal of Pharmacy Practice, 1997
The introduction of a new class of anti-HIV agents, the protease inhibitors, has given new hope to patients with HIV infection. Use of these agents requires the pharmacist to have a complete knowledge of phar macokinetics, adverse reactions, drug-drug interactions, and resistance profiles.
Scott M. Bonnema, Catherine M. Oliphant
openaire +2 more sources
The introduction of a new class of anti-HIV agents, the protease inhibitors, has given new hope to patients with HIV infection. Use of these agents requires the pharmacist to have a complete knowledge of phar macokinetics, adverse reactions, drug-drug interactions, and resistance profiles.
Scott M. Bonnema, Catherine M. Oliphant
openaire +2 more sources
The intracellular pharmacology of the antiretroviral protease inhibitors in a clinical setting.
, 2004 Jennifer Lynn Ford
openalex +2 more sources
Clinical Pharmacokinetics, 2015
Boceprevir is a potent, orally administered ketoamide inhibitor that targets the active site of the hepatitis C virus (HCV) non-structural (NS) 3 protease. The addition of boceprevir to peginterferon plus ribavirin resulted in higher rates of sustained virologic response (SVR) than for peginterferon plus ribavirin alone in phase III studies in both ...
Larissa Wenning +4 more
openaire +3 more sources
Boceprevir is a potent, orally administered ketoamide inhibitor that targets the active site of the hepatitis C virus (HCV) non-structural (NS) 3 protease. The addition of boceprevir to peginterferon plus ribavirin resulted in higher rates of sustained virologic response (SVR) than for peginterferon plus ribavirin alone in phase III studies in both ...
Larissa Wenning +4 more
openaire +3 more sources
Journal of Cellular Biochemistry, 2018
AbstractProtease inhibitors (PIs) are crucial drugs in highly active antiretroviral therapy for human immunodeficiency virus‐1 (HIV‐1) infections. However, resistance owing to mutations challenge the long‐term efficacy in the medication of HIV‐1‐infected individuals.
Chirasmita Nayak +2 more
openaire +2 more sources
AbstractProtease inhibitors (PIs) are crucial drugs in highly active antiretroviral therapy for human immunodeficiency virus‐1 (HIV‐1) infections. However, resistance owing to mutations challenge the long‐term efficacy in the medication of HIV‐1‐infected individuals.
Chirasmita Nayak +2 more
openaire +2 more sources
Pharmacology, 2013
The addition of NS3/4A protease inhibitors boceprevir and telaprevir to pegylated interferon (Peg-IFN)-α and ribavirin for the treatment of hepatitis C virus (HCV) genotype 1-infected patients has led to higher rates of virological response and adverse events.
L. Milazzo +7 more
openaire +3 more sources
The addition of NS3/4A protease inhibitors boceprevir and telaprevir to pegylated interferon (Peg-IFN)-α and ribavirin for the treatment of hepatitis C virus (HCV) genotype 1-infected patients has led to higher rates of virological response and adverse events.
L. Milazzo +7 more
openaire +3 more sources
Clinical pharmacology of human immunodeficiency virus-1 protease inhibitors.
, 2004 Marta Boffito
openalex +2 more sources
Journal of Medicinal Chemistry, 2010
A series of new thienyl ring containing analogues of nelfinavir and saquinavir with different substitution patterns were synthesized from suitable enantiopure diols. Their inhibitory activity against wild type recombinant HIV-1 protease was evaluated.
Carlo Bonini +8 more
openaire +5 more sources
A series of new thienyl ring containing analogues of nelfinavir and saquinavir with different substitution patterns were synthesized from suitable enantiopure diols. Their inhibitory activity against wild type recombinant HIV-1 protease was evaluated.
Carlo Bonini +8 more
openaire +5 more sources
HIV protease inhibitors: pharmacologic and metabolic distinctions.
AIDS (London, England), 1999In the earlier era of nucleoside analogue antiretroviral therapy, considerations of pharmacologic drug-drug interactions were only a small factor in choosing optimal therapies for patients with HIV infection. However, pharmacologic considerations are critical for selecting and managing the current multiple-drug antiretroviral regimens that include one ...
openaire +1 more source
Radiotheranostics in oncology: Making precision medicine possible
Ca-A Cancer Journal for Clinicians, 2023Eric O Aboagye
exaly